Trial · NCT07907939
Microneedling-Assisted i-PRF for Interdental Papilla Deficiency
NCT07907939, Not applicable, Not yet recruiting, Ehab Ayman Hussien Mohamed Abdelaal
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Microneedling-Assisted i-PRF for Interdental Papilla Deficiency. Trials, record NCT07907939. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07907939
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Microneedling-Assisted i-PRF for Interdental Papilla Deficiency
- NCT number
- NCT07907939
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Ehab Ayman Hussien Mohamed Abdelaal
- Conditions
- Interdental Papilla Deficiency
- Interventions
- Autologous injectable platelet-rich fibrin (i-PRF), Microneedling of the interdental papilla
- First posted
- 2026-10-30
- Last updated
- 2026-11-04
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in black triangle height | Baseline, 1 month, 3 months, and 6 months following treatment | Change in the height of the open gingival embrasure (black triangle), measured in millimeters using a calibrated UNC-15 periodontal probe with a standardized acrylic stent. A reduction in height indicates improvement. |
| Secondary | Change in Plaque Index | Baseline, 1 month, 3 months, and 6 months following treatment | Plaque accumulation assessed using the Silness and Loe Plaque Index on a scale from 0 to 3. Higher scores indicate greater plaque accumulation. |
| Secondary | Change in Gingival Index | Baseline, 1 month, 3 months, and 6 months following treatment | Gingival inflammation assessed using the Loe and Silness Gingival Index on a scale from 0 to 3. Higher scores indicate more severe gingival inflammation. |
| Secondary | Change in probing pocket depth | Baseline, 1 month, 3 months, and 6 months following treatment | Probing pocket depth measured in millimeters using a UNC-15 periodontal probe to monitor periodontal conditions at the treated sites. |
| Secondary | Patient satisfaction with esthetic appearance | At the end of the 6-month follow-up | Patient satisfaction with esthetic appearance assessed using a visual analogue scale from 0 to 10, where 0 represents unsatisfied/worst imaginable appearance and 10 represents very satisfied/best imaginable appearance. Participants review pretreatment clinical photographs before completing the scale. |
| Secondary | Change in gingival crevicular fluid MMP-9 levels | Baseline, 2 weeks, 1 month, 3 months, and 6 months following treatment | Matrix metalloproteinase-9 (MMP-9) concentration in gingival crevicular fluid, reported in ng/mL. Fluid is collected with paper points for 30 seconds and measured using a human MMP-9 ELISA kit in duplicate by a blinded laboratory analyst. |
| Secondary | Change in gingival crevicular fluid TIMP-1 levels | Baseline, 2 weeks, 1 month, 3 months, and 6 months following treatment | Tissue inhibitor of metalloproteinase-1 (TIMP-1) concentration in gingival crevicular fluid, reported in ng/mL. Fluid is collected with paper points for 30 seconds and measured using a human TIMP-1 ELISA kit in duplicate by a blinded laboratory analyst. |
| Secondary | Change in gingival crevicular fluid periostin levels | Baseline, 2 weeks, 1 month, 3 months, and 6 months following treatment | Periostin concentration in gingival crevicular fluid, reported in ng/mL. Fluid is collected with paper points for 30 seconds and measured using a human periostin ELISA kit in duplicate by a blinded laboratory analyst. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07907939
GET https://conductscience.org/api/trials/v1/NCT07907939/registered